A vial sold online as retatrutide may not hold any retatrutide at all. On September 14, 2026, Australia's medicines regulator said it had tested one such counterfeit retatrutide product after the person who injected it was hospitalized with uncontrollable vomiting and a torn esophagus. There was no retatrutide inside. There was semaglutide, the active ingredient in Ozempic and Wegovy, at roughly eight times the strength of the approved semaglutide products the regulator has assessed.

Retatrutide is an experimental weight-loss drug from Eli Lilly, and no major medicines regulator has approved it. Anything sold under its name outside Lilly's trials is not the drug those trials tested, and someone buying from an anonymous seller has no way to know what they actually have.

What the TGA found in the counterfeit retatrutide

The Therapeutic Goods Administration (TGA) is Australia's version of the FDA. Its September 14 safety alert says a consumer who used a product sold as retatrutide "experienced uncontrollable vomiting, resulting in a torn oesophagus, and required treatment in hospital." The esophagus is the tube that carries food from the throat to the stomach, and forceful vomiting can tear it.

Testing the product in its original unmarked vial, the TGA's lab found undeclared semaglutide and no retatrutide. The semaglutide was about eight times the level found in approved semaglutide products on Australia's medicines register.

That number matters. Semaglutide is started low and raised slowly, partly because nausea and vomiting climb with the dose. The FDA says it has received adverse-event reports, some serious, tied to doses beyond what the approved labels describe, with nausea and vomiting among the symptoms. The Australian product was sold as one drug and delivered a large, unmeasured dose of another.

Is online retatrutide real?

Not in any way a buyer can check. Retatrutide is a weekly injection in late-stage Lilly trials called TRIUMPH. It acts on three hormone receptors, one more than tirzepatide; our retatrutide overview explains the science. On July 23, 2026, Lilly said it plans to submit an application to the FDA in the first quarter of 2027.

As of September 23, 2026, the day this article was written, the FDA's page on unapproved GLP-1 drugs, last updated September 1, said retatrutide is not a component of any FDA-approved drug and "has not been found safe and effective for any condition." The TGA's alert adds that retatrutide "has not been approved by the TGA or any comparable international regulator." Lilly's court fight with sellers is covered in our retatrutide lawsuit explainer.

A name on a website or a vial proves nothing about the contents. If retatrutide's trial numbers are what brought you here, the closest medicines with long trial records behind them are tirzepatide, which acts on two of the same receptors, and semaglutide.

The Australian vial was not a one-off

In June, Victoria's Chief Health Officer reported six cases of acute liver injury since January in people who used products labeled "Retatrutide", "Reta", "R-10" or "R-20", and said a contaminant was a possible cause.

In a 2026 case report from Edinburgh, a man with type 1 diabetes developed severe vomiting, rising ketones (acids the body makes when it runs short of insulin) and acute kidney injury after injecting an online product marketed as retatrutide. The authors could not prove the product caused it, because he also had a gut infection.

The wrong-drug problem has a track record, too. Hospitals in Italy and the Netherlands have described people in comas after injecting "semaglutide" bought without a prescription that turned out to contain insulin.

What this does not mean

It doesn't make semaglutide the villain. The Australian case involved semaglutide at many times the expected strength, in an unmarked vial, injected by someone who had been sold something else. Prescribed semaglutide starts low, rises on a schedule the prescriber sets, and arrives with a label naming the drug and its strength.

Nor is every fake secretly semaglutide. The Victorian liver cases point to contamination, and the Dutch and Italian products held insulin. An unmarked vial's contents are simply unknown.

And it doesn't make retatrutide's research shaky. Lilly's trial data describe Lilly's drug. They say nothing about a vial from a stranger.

What CBS News found behind the trust seal

Two days after the TGA alert, CBS News published an investigation into who was selling retatrutide in the US. It found more than 80 businesses promoting the drug while displaying a seal from LegitScript, a private company whose certification helps health businesses advertise on Facebook, Instagram, Google and YouTube. CBS reported that prescribing or selling retatrutide breaks LegitScript's own standards.

At least 35 of those companies showed the certification on the same page where they promoted retatrutide. Some that no longer appeared in LegitScript's database still displayed its shield. One advertised retatrutide with a photo of a vial labeled "Legit. Script. Certified." LegitScript's chief executive told CBS that all of them had been flagged by its monitoring; some gave up certification, some were suspended and the rest were making changes.

How to spot a fake LegitScript seal

A seal on a web page is a picture, and anyone can paste one in. LegitScript published a guide to checking its seal on September 17, the day after the CBS story. The useful parts:

  • A real seal is live. Clicking it should open a status page on legitscript.com, not just a bigger image.
  • Check at the source. Search the site's address in LegitScript's database, which shows current status. Certification can be lost quickly.
  • Watch for look-alikes. LegitScript names "Legit Script" written as two words, slightly wrong colors or fonts, and blurry copies of the shield as warning signs.

None of this makes the seal worthless. A current, verified certification tells you a business has been reviewed against published rules. It is not a lab test of what's in a vial, and it cannot vouch for a drug no regulator has approved.

What a prescribed route does differently

The real contrast is anonymous versus accountable; our guide to gray-market peptides covers the wider market. Three differences matter here:

  • A named prescriber. A clinician licensed in your state reviews your history before anything is written, and you can check that license yourself.
  • A pharmacy of record. A state-licensed pharmacy fills the prescription and labels it with the drug, the strength, your name and the prescriber: everything the Australian vial lacked.
  • A trail if something goes wrong. The prescriber, the pharmacy and FDA's MedWatch program all have a record to start from.

Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. A licensed provider may still prescribe one when it fits your history; that decision is between you and your doctor. A licensed provider reviews every request, and not everyone qualifies.

The FDA's red flags

The FDA's list of warning signs for buying these drugs online includes a seller that doesn't require screening and a prescription from a licensed doctor, has no doctor to answer questions after the medicine arrives, or ships a label with spelling errors or a pharmacy name that might be fake.

What to watch next

Three open questions. Whether the TGA traces the vial to its source, which its alert says it is trying to do. Whether LegitScript's cleanup holds, since CBS found new retatrutide ads still appearing after the first round of removals. And Lilly's planned FDA submission in early 2027, which would start a review, not set a launch date.

Until a regulator finishes that review, an unmarked vial sold as retatrutide tells you what the seller wants you to believe, not what's inside.